Brand Name

Celontin

Generic Name
Methsuximide
View Brand Information
FDA approval date: February 08, 1957
Classification: Anti-epileptic Agent
Form: Capsule

What is Celontin (Methsuximide)?

Methsuximide is indicated for the control of absence seizures that are refractory to other drugs.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Nonsilyl bicyclic secondary amine catalyzed Michael addition of nitromethane to β,β-disubstituted α,β-unsaturated aldehydes.
Nonsilyl bicyclic secondary amine catalyzed Michael addition of nitromethane to β,β-disubstituted α,β-unsaturated aldehydes.
Journal: Organic & biomolecular chemistry
Published: April 17, 2025
From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications.
From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications.
Journal: Pharmacology & therapeutics
Published: August 28, 2024
Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages.
Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages.
Journal: Therapeutic drug monitoring
Published: August 08, 2018
View All Latest Advances